You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

November 14, 2014

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

FDA analysis of dabigatran versus warfarin for nonvalvular AF questioned

A new study has found a greater bleeding risk associated with the use of dabigatran (Pradaxa, Boehringer Ingelheim) in patients with nonvalvular atrial fibrillation (AF) than that cited on initial FDA approval of the drug. » Get the data for both studies

Newly approved blood test predicts organ transplant rejection in children

FDA has approved a first-of-its-kind, personalized blood test (Pleximmune) to predict the likelihood of organ rejection in children with liver or intestine transplants. » Read what organ rejection can lead to

Continuing Education

MTM essentials for weight management

This month's CE activity is part of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to educate pharmacists about the prevalence, health consequences, and nonpharmacologic and pharmacologic treatment options for obesity, with a focus on the recommendations made in the 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exam and earn up to 2 CPE credits, click here to log in with the session code 14DT12-FKX42.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Drugs in Perspective: Otezla (apremilast)

Otezla (apremilast) was approved for a second indication, the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy. » Read more on the drug's relevance, cost, and place in therapy

 

RELATED ARTICLES

Can dabigatran be used in pregnant women?

Genomic complexity slows childhood disease research

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group